Source Count: 15 | Weighted Score: 30 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: March 11, 2026
Keywords: psychedelics, 5-HT2A receptor, serotonin, tryptamines, psilocybin, LSD, DMT, mescaline, MDMA, neuroplasticity, default mode network, claustrum, entropy, ego dissolution, neuroimaging, psychedelic therapy, pharmacology, hallucinogen, entheogens, receptor binding, signal transduction, cortical excitability
Category Tags: molecular biology, neurochemistry, pharmacology, consciousness, altered states
Cross-References: Y_1_01 — Psychedelic Experiences · Y_1_04 — Entheogens · Z_2_03 — Biochemistry · K_2_10 — Neural Entrainment · K_1_01 — Consciousness Overview

QUICK SUMMARY

Psychedelic neurochemistry — the molecular-level study of how psychedelic compounds alter brain function to produce their characteristic effects (visual hallucinations, synesthesia, ego dissolution, mystical-type experiences, emotional intensification, and altered time perception) — has undergone a dramatic scientific renaissance since the early 2000s. After decades of suppression following the 1970 Controlled Substances Act and equivalent international prohibitions, rigorous neuroscientific investigation has revealed in unprecedented detail how these molecules interact with neural receptors, alter intracellular signaling cascades, reshape large-scale brain network dynamics, and potentially promote lasting neuroplasticity. The central pharmacological finding is that the "classic" psychedelics — psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine — the prodrug of psilocin), LSD (lysergic acid diethylamide), DMT (N,N-dimethyltryptamine), and mescaline (3,4,5-trimethoxyphenethylamine) — produce their primary subjective effects through agonism at the serotonin 5-HT₂A receptor, a G protein-coupled receptor (GPCR) densely expressed in cortical pyramidal neurons, particularly in layer V of the prefrontal cortex. Blocking 5-HT₂A with the selective antagonist ketanserin abolishes the subjective effects of psilocybin in humans (Vollenweider et al., 1998; Quednow et al., 2003) — establishing causal necessity. However, the story is far more complex than simple receptor binding: psychedelics activate multiple downstream signaling pathways (Gq/11 → phospholipase C → IP₃/DAG, but also β-arrestin-mediated pathways), influence glutamatergic neurotransmission via cortical pyramidal → thalamocortical circuits, and produce large-scale changes in brain network dynamics — particularly a dramatic reduction in default mode network (DMN) activity and connectivity, coupled with a global increase in functional connectivity entropy (the brain accesses configurations it does not normally visit). Robin Carhart-Harris and colleagues (2014) proposed the "entropic brain hypothesis" — that psychedelics increase the entropy (informational richness and disorder) of spontaneous cortical activity, dissolving the normally constrained repertoire of brain states that underlies ordinary waking consciousness and the stable sense of self. This entropic model offers a mechanistic account of ego dissolution — the phenomenologically central psychedelic experience of the boundary between self and world dissolving. Recent neuroplasticity documented evidence has demonstrated that psychedelics (particularly DMT and psilocybin) promote dendritic spine growth and synaptogenesis in cortical neurons — effects mediated via TrkB (tropomyosin receptor kinase B) and mTOR (mechanistic target of rapamycin) signaling pathways — raising the possibility that the lasting therapeutic effects of psychedelic-assisted therapy (for depression, PTSD, addiction) may result not just from the acute subjective experience but from structural neural remodeling.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Experimentally Confirmed)

1.1 5-HT₂A Receptor — The Central Target

• The serotonin 5-HT₂A receptor is a G protein-coupled receptor (GPCR) with seven transmembrane domains:
• Distribution: densely expressed in neocortical pyramidal neurons, particularly layer V of the prefrontal, parietal, and temporal cortices — regions critical for sensory processing, executive function, and self-referential thought
• Also expressed in the claustrum (Crick & Koch's proposed seat of consciousness), thalamus, and limbic structures
• Endogenous ligand: serotonin (5-hydroxytryptamine, 5-HT) — but endogenous trace amines (DMT, 5-MeO-DMT) may also be natural ligands
• Proof of necessity: Vollenweider et al. (1998) demonstrated that pre-treatment with the selective 5-HT₂A antagonist ketanserin completely blocked the subjective effects of psilocybin in a placebo-controlled, double-blind design
• This established that 5-HT₂A activation is necessary and sufficient for the primary phenomenology of classic psychedelics
• Further confirmed by PET imaging showing that subjective intensity correlates with 5-HT₂A receptor occupancy

1.2 Structure-Activity Relationships

• Classic psychedelics fall into two major structural families, both targeting 5-HT₂A:
• Tryptamines (indole-ring based — structurally related to serotonin itself):
• Psilocybin / psilocin: the 4-hydroxy-DMT found in >200 species of Psilocybe, Panaeolus, and other mushroom genera. Psilocybin is a prodrug — dephosphorylated to psilocin by alkaline phosphatase in vivo. Psilocin binds 5-HT₂A with Ki ≈ 6–10 nM
• LSD (lysergic acid diethylamide): an ergoline (modified tryptamine with additional ring systems — derived from ergot alkaloids). LSD is the most potent classic psychedelic — active at doses as low as 20–25 μg in humans. Binds 5-HT₂A with Ki ≈ 1–3 nM. Unusually long duration (8–12 hours) partly explained by LSD being "trapped" in the 5-HT₂A binding pocket by a "lid" formed by extracellular loop 2 (ECL2 — Wacker et al., 2017, Cell)
• DMT (N,N-dimethyltryptamine): found endogenously in human cerebrospinal fluid (Barker et al., 2012) and in many plants (Psychotria viridis, Mimosa hostilis). Short-acting (~15–30 minutes when smoked/injected); orally active only with MAO inhibition (as in ayahuasca — DMT + β-carboline MAOIs from Banisteriopsis caapi). Binds 5-HT₂A with Ki ≈ 75–130 nM (relatively low affinity; high doses required)
• Phenethylamines (phenyl-ring based):
• Mescaline (3,4,5-trimethoxyphenethylamine): the psychedelic compound in peyote (Lophophora williamsii) and San Pedro (Trichocereus pachanoi). Active dose ~200–400 mg (orders of magnitude higher than LSD). Binds 5-HT₂A with modest affinity; also significant activity at 5-HT₂C
• The 2C-x series (Shulgin): phenethylamine derivatives with varying substitutions, all acting primarily at 5-HT₂A

1.3 Downstream Signaling — Biased Agonism

• 5-HT₂A is coupled to Gq/11 G proteins, activating phospholipase C (PLC) → hydrolysis of PIP₂ → production of IP₃ (inositol trisphosphate — calcium release from ER) and DAG (diacylglycerol — activates protein kinase C):
• This canonical pathway drives cortical neuronal excitation
• However, psychedelics show biased agonism — they preferentially activate certain downstream pathways over others compared to serotonin itself:
• LSD and psilocin preferentially recruit β-arrestin-2 (compared to serotonin's more balanced Gq/β-arrestin activation) — this "biased signaling" may contribute to psychedelic-specific effects distinct from ordinary serotonergic transmission
• Recent work (Olson lab, UC Davis) has identified that the neuroplasticity effects of psychedelics (dendritic growth, synaptogenesis) require TrkB (BDNF receptor) and mTOR signaling — potentially via intracellular 5-HT₂A activation (psychedelics may act on intracellular receptors, not just cell-surface receptors — see Bhatt et al., 2024)
• Glutamate release: 5-HT₂A activation on layer V pyramidal neurons increases glutamate release in the prefrontal cortex — this glutamatergic surge is critical to psychedelic effects and can be blocked by mGluR2/3 agonists

1.4 Default Mode Network Disruption

• Neuroimaging studies (fMRI, MEG, PET) have consistently shown that psychedelics reduce activity and connectivity within the default mode network (DMN) — the set of brain regions (medial prefrontal cortex, posterior cingulate cortex, angular gyrus, hippocampus) most active during rest, self-referential thought, autobiographical memory, and mind-wandering:
• Carhart-Harris et al. (2012): psilocybin reduced blood flow and BOLD signal in the medial prefrontal cortex and posterior cingulate cortex — the two main hubs of the DMN. Reductions in DMN activity correlated with subjective reports of ego dissolution
• Palhano-Fontes et al. (2015): similar DMN reduction patterns under ayahuasca (DMT + MAOIs)
• Tagliazucchi et al. (2016) and Carhart-Harris et al. (2016): LSD increased global functional connectivity — brain regions that do not normally communicate became transiently connected, while the normally integrated DMN became desynchronized
• Interpretation: the DMN's constrained activity patterns normally underlie the stable sense of self, narrative identity, and the filtering of experience. Psychedelics dissolve these constraints, allowing the brain to access a wider repertoire of states — correlating with the subjective experience of "ego death," "unity," and radically altered perception

1.5 Neuroplasticity — "Psychoplastogens"

• Olson et al. (2018) coined the term "psychoplastogens" — substances that promote rapid structural and functional neural plasticity:
• In vitro and in vivo published findings demonstrate that LSD, DMT, and DOI (a 5-HT₂A agonist) promote:
• Dendritic arbor complexity — increased dendritic branching and length in cortical neurons
• Dendritic spine density — increased number of dendritic spines (the primary postsynaptic sites of excitatory synapses)
• Synaptogenesis — formation of new functional synapses
• These effects are comparable in magnitude to those of BDNF (brain-derived neurotrophic factor) — the brain's primary endogenous growth factor
• Mediated via TrkB and mTOR signaling pathways — rapamycin (mTOR inhibitor) blocks the neuroplasticity effects
• Clinical implication: the rapid antidepressant effects of psilocybin may result from structural neural remodeling in prefrontal and limbic circuits — not just from the acute subjective experience
• Shao et al. (2021): a single dose of psilocybin increased dendritic spine density in mouse frontal cortex within 24 hours, with effects lasting at least one month

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 The Entropic Brain Hypothesis

• Carhart-Harris et al. (2014) — "The Entropic Brain: A Theory of Conscious States Informed by Neuroimaging Research with Psychedelic Drugs":
• Proposes that the quality of any conscious state can be indexed by the entropy (measured as Lempel-Ziv complexity, Shannon entropy, or similar metrics) of spontaneous cortical activity
• Normal waking consciousness occupies a "critical" zone — ordered enough for stable cognition but flexible enough for adaptive behavior
• Psychedelic states shift the brain toward a supercritical regime — higher entropy, greater disorder, more diverse functional connectivity patterns. This correlates with ego dissolution, unconstrained cognition, and novel associations
• Depressive/compulsive states shift the brain toward a subcritical regime — excessively ordered, rigid, repetitive patterns. This may explain why psychedelics show therapeutic efficacy against these conditions — by temporarily disrupting rigid neural patterns and allowing "resetting"
• Debate: the entropic brain hypothesis is influential but not universally accepted — researchers argue it is too metaphorical, difficult to operationalize precisely, or conflates different measures of neural complexity

2.2 The Claustrum Hypothesis

• Crick & Koch (2005) proposed that the claustrum — a thin, sheet-like structure beneath the insular cortex with reciprocal connections to virtually all cortical regions — might function as a "conductor of consciousness," integrating information from different sensory modalities into unified experience:
• Doss et al. (2022): psilocybin significantly reduced claustral connectivity to auditory and frontal networks in an fMRI study — suggesting that psychedelic ego dissolution may involve claustral desynchronization
• Whether the claustrum is a genuine "consciousness center" or simply one integration hub among many remains debated

2.3 Endogenous DMT and the Pineal Gland

• DMT has been detected in trace quantities in human cerebrospinal fluid (Barker et al., 2012) and in rat brain tissue (Dean et al., 2019):
• The functional role of endogenous DMT is unknown — it may serve as a neuromodulator, a byproduct of tryptophan metabolism, or have functions unrelated to psychedelic-type experiences
• Rick Strassman (2001, DMT: The Spirit Molecule) popularized the hypothesis that endogenous DMT release from the pineal gland produces near-death experiences, mystical states, and dreaming
• Evidence status: while DMT is endogenous, there is no confirmed evidence that the pineal gland produces DMT in quantities sufficient to produce psychedelic effects, or that endogenous DMT release mediates any specific conscious experience. The hypothesis remains speculative

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Non-Hallucinogenic Psychoplastogens

• David Olson's lab (UC Davis) and others are developing non-hallucinogenic analogs of psychedelics that retain neuroplasticity-promoting effects without producing subjective psychedelic experiences:
• Tabernanthalog (TBG — Olson et al., 2020): an ibogaine analog that promotes dendritic growth and shows antidepressant effects in animal models without apparent hallucinogenic properties
• If successful, these compounds could deliver the therapeutic benefits of psychedelic-assisted therapy (neural plasticity, antidepressant effects) without the intense subjective experience, the need for trained therapists, or the regulatory challenges of Schedule I compounds
• Whether the acute subjective experience is necessary for lasting therapeutic benefit — or whether the neuroplasticity alone is sufficient — is one of the central unanswered questions in the field

3.2 Sigma and Kappa Opioid Receptor Interactions

• Some psychedelic effects — particularly those of salvinorin A (from Salvia divinorum, a kappa-opioid receptor agonist with no 5-HT₂A activity), ibogaine (which acts on multiple receptor systems including NMDA, sigma, nicotinic, and serotonin), and high-dose DMT — may involve receptor systems beyond 5-HT₂A:
• These non-classical pharmacologies are poorly understood and suggest that the psychedelic landscape is neurochemically broader than the 5-HT₂A-centered model captures

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 The Pineal Gland Floods the Brain with DMT at Death

• [UNCONFIRMED] Strassman's hypothesis that the pineal gland releases massive quantities of DMT at the moment of death, producing near-death experiences, has no direct experimental support in humans. While endogenous DMT exists, the quantities detected are far below psychoactive thresholds, and the mechanism for a hypothetical pineal "flood" has not been demonstrated.

4.2 Psychedelics "Unlock" Unused Brain Capacity

• [INCORRECT] The popular myth that humans "only use 10% of their brain" and that psychedelics "unlock" the rest is neurologically false. The brain is fully active at all times. What psychedelics do is alter the pattern of activity — disrupting default networks and enabling unusual functional connectivity, not activating previously dormant regions.

IMAGES

No images assigned yet.

COUNTER-ARGUMENTS & CRITICISMS

• Reductionism: neuroscientific accounts of psychedelic experience risk reducing profound subjective phenomena (ego dissolution, mystical unity, encounter with entities) to "mere" receptor binding and signal transduction — a criticism applicable to all neuroreductive approaches to consciousness
• Translational gap: much of the neuroplasticity evidence comes from in vitro cell culture and rodent models — whether identical dendritic remodeling occurs in human brains at therapeutic doses remains to be definitively confirmed with post-mortem or advanced in vivo techniques
• Set and setting: pharmacological mechanisms cannot fully explain the psychedelic experience — psychological preparation, physical environment, and social context profoundly shape outcomes. The neurochemistry is necessary but not sufficient for understanding the full phenomenon
• Safety concerns: while classic psychedelics have low physiological toxicity (no lethal dose identified for psilocybin, LSD, or DMT in humans from direct pharmacological effects), psychological risks (anxiety, panic, psychotic episodes in predisposed individuals, HPPD) are real and require careful clinical management

BIBLIOGRAPHY

1. Vollenweider, F.X. et al | 1998 | "Psilocybin Induces Schizophrenia-Like Psychosis in Humans via a Serotonin-2 Agonist Action" | NeuroReport | ∅ | 9.17::3897–3902 | ∅ | ∅ | doi:10.1097/00001756-199812010-00024 | ∅ | ∅ | ∅
2. Carhart-Harris, R.L. et al | 2012 | "Neural Correlates of the Psychedelic State as Determined by fMRI Studies with Psilocybin" | PNAS | ∅ | 109.6::2138–2143 | ∅ | ∅ | doi:10.1073/pnas.1119598109 | ∅ | ∅ | ∅
3. Carhart-Harris, R.L. et al | 2014 | "The Entropic Brain: A Theory of Conscious States Informed by Neuroimaging Research with Psychedelic Drugs" | Frontiers in Human Neuroscience | ∅ | 8::20 | ∅ | ∅ | doi:10.3389/fnhum.2014.00020 | ∅ | ∅ | ∅
4. Ly, C. et al | 2018 | "Psychedelics Promote Structural and Functional Neural Plasticity" | Cell Reports | ∅ | 23.11::3170–3182 | ∅ | ∅ | doi:10.1016/j.celrep.2018.05.022 | ∅ | ∅ | ∅
5. Wacker, D. et al | 2017 | "Crystal Structure of an LSD-Bound Human Serotonin Receptor" | Cell | ∅ | 168.3::377–389 | ∅ | ∅ | doi:10.1016/j.cell.2016.12.033 | ∅ | ∅ | ∅
6. Nichols, D.E | 2016 | "Psychedelics" | Pharmacological Reviews | ∅ | 68.2::264–355 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
7. Carhart-Harris, R.L. et al | 2016 | "Neural Correlates of the LSD Experience Revealed by Multimodal Neuroimaging" | PNAS | ∅ | 113.17::4853–4858 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Shao, L.-X. et al | 2021 | "Psilocybin Induces Rapid and Persistent Growth of Dendritic Spines in Frontal Cortex in Vivo" | Neuron | ∅ | 109.16::2535–2544 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Barker, S.A. et al | 2013 | "LC/MS/MS Analysis of the Endogenous Dimethyltryptamine Hallucinogens, Their Precursors, and Major Metabolites in Rat Pineal Gland Microdialysate" | Biomedical Chromatography | ∅ | 27.12::1690–1700 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
10. Doss, M.K. et al | 2021 | "Psilocybin Therapy Increases Cognitive and Neural Flexibility in Patients with Major Depressive Disorder" | Translational Psychiatry | ∅ | 11::574 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
11. Strassman, R | 2001 | ∅ | DMT: The Spirit Molecule | ∅ | ∅ | Park Street Press | ∅ | isbn:9798587592179 | ∅ | ∅ | ∅
12. Olson, D.E | 2018 | "Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics" | Journal of Experimental Neuroscience | ∅ | 12::1–4 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
13. Preller, K.H. et al. e35082 | 2018 | "Changes in Global and Thalamic Brain Connectivity in LSD-Induced Altered States of Consciousness Are Attributable to the 5-HT2A Receptor" | eLife | ∅ | 7:: | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
14. González-Maeso, J. et al | 2007 | "Hallucinogens Recruit Specific Cortical 5-HT₂A Receptor-Mediated Signaling Pathways to Affect Behavior" | Neuron | ∅ | 53.3::439–452 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
15. Vollenweider, F.X.; Preller, K.H | 2020 | "Psychedelic Drugs: Neurobiology and Potential for Treatment of Psychiatric Disorders" | Nature Reviews Neuroscience | ∅ | 21.11::611–624 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from cross-cutting keyword analysis — "psychedelic|5-HT2A|tryptamine|DMT|psilocybin|LSD" appears across 9 docs in 4 sections. Last Updated: March 11, 2026